Rgenta Therapeutics
Cambridge
About Rgenta Therapeutics
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $116.9M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2023)
- Website: rgentatx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/rgenta-therapeutics-104169 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.